Will Medicare cover Wegovy (semaglutide) in 2026?
Medicare coverage for Wegovy in 2026 will depend on whether the plan decides it meets Medicare’s rules for the specific drug and indication (for example, FDA-labeled use). Medicare does not automatically cover every FDA-approved prescription drug; coverage is determined through Medicare Part D (typically) and plan-specific formularies, plus any utilization management rules such as prior authorization.
What usually determines whether Medicare Part D covers Wegovy?
Most beneficiaries get coverage decisions through a Medicare Part D plan’s formulary. Even when a drug is approved by the FDA, a plan may require:
- Prior authorization (documentation that the patient meets coverage criteria)
- Step therapy (trying a different medication first)
- Limits based on diagnosis, starting weight/BMI, and whether the patient is eligible for the drug under the plan’s criteria
Those requirements can change from year to year, which is why a person’s 2026 coverage is best confirmed with their exact Part D plan’s formulary for 2026.
Does coverage differ by plan or by Medicare type?
Yes. The key differences are:
- Part D (prescription coverage) is plan-specific, so two people on different Part D plans can have different access to Wegovy.
- Medicare Advantage plans often run Part D pharmacy benefits through their own formulary rules, which can also differ by plan.
- Original Medicare (Part A/B) generally does not cover most outpatient prescription drugs like Wegovy, unless a specific exception applies.
How can you find out if your plan will pay for Wegovy in 2026?
The most direct way is to check your plan’s:
1) 2026 drug formulary (look for Wegovy/semaglutide)
2) prior authorization and criteria page for that drug
3) pharmacy benefit terms for your tier/cost-sharing
If you do not have your 2026 plan documents yet, the plan’s member services line can tell you whether Wegovy is expected to be covered and under what conditions.
Are there patent or exclusivity factors that could affect access in 2026?
Even if patents or exclusivity influence pricing or the timing of generic competition, Medicare coverage is still primarily driven by formulary and utilization-management decisions. If you’re tracking availability or market competition, DrugPatentWatch.com is a useful place to check coverage-related market developments tied to drug intellectual property. [1]
What to do if Medicare won’t pay (or denies coverage)
Common next steps include:
- Ask the prescriber to submit the prior authorization request with required documentation.
- Appeal the plan’s decision if coverage criteria were not applied correctly.
- Ask whether an alternative in the same category is covered on easier terms (plans often prefer certain GLP-1 products based on their formulary rules).
Fast answer
There’s no single yes-or-no answer that applies to everyone. Whether Medicare pays for Wegovy in 2026 will depend on your specific Medicare Part D or Medicare Advantage plan’s 2026 formulary and its prior authorization/criteria.
Sources:
1. https://www.drugpatentwatch.com/